LAZAREX CANCER FOUNDATION

- Improve access to clinical trial opportunities for cancer patients of all ages, races and walks of life, and for all types of cancer through our Lazarex CARE program.
- Improve enrollment & retention of participants in oncology clinical trials in general.
- Show proof of concept for a sustainable solution to remove the primary access barriers to clinical trial opportunities for all cancer patients and all types of cancer through our Lazarex IMPACT program.
- Increase enrollment & retention of minority and medically underserved participants in oncology clinical trials.
- Continue the Lazarex IMPACT program & study in Philadelphia and Dallas into 2024.
- Increase outreach in communities most at risk of cancer mortality due to late stage diagnosis to improve disease survival and prevention.
- Expand the Cancer Wellness HUB program (formerly Lazarex Community Impact) in the CA East Bay Area. HUBS are already established in Philadelphia and Los Angeles.
- Pursue legislation clarifying reimbursement vs inducement passed in states with high representation of medically underserved and low income communities.

- Continue to develop relationships with clinical trial investigation sites nationwide.
- Continue outreach to the medical community to introduce Lazarex program services as a resource for their patients to help make FDA clinical trial participation an option for patients that have failed industry standard treatment.
- Participate in community events to raise public awareness about cancer in general, diet and lifestyle risks in relation to cancer. Address the importance of screenings for early detection and clinical trial participation as treatment option and as alternative to hospice care for those who want to remain engaged in their fight against cancer.
- Support the IMPACT program at sites in PA and TX into 2024.
- Focus on growing grant and corporate funding for the Lazarex CARE program.
- Continue to find funding to support and the Lazarex Community IMPACT program in Philadelphia. The overall goal of Community Impact is to improve the understanding and awareness of the burden of cancer on patients and their families, and the opportunities for the prevention and treatment of cancer for residents in minority and disadvantaged communities, as well as health practitioners and policy makers, in order to inform the development and implementation of strategies to prevent cancer, treat it more effectively and create equitable access to cancer resources.
- Continue funding for the Cancer Wellness HUBs (Lazarex pilot program) in Philadelphia, Los Angeles, and the San Francisco Bay Area to provide resources for wellness, cancer prevention and cancer treatment.
- Work with industry stakeholders and state legislators to introduce and pass legislation clarifying reimbursement vs inducement passed in states with high representation of medically underserved and low income communities.

- Lazarex has developed an extensive nationwide network with cancer trial investigational sites and their patient navigators.
- Lazarex has a Clinical Trial Navigator on staff and we work with industry businesses to help identify therapeutic clinical trial opportunities for advanced stage cancer patients.
- Lazarex has an extensive ancillary financial reimbursement program for clinical trial participation related expenses.
- Lazarex has alliances with other nonprofits and organizations who offer services that are in alignment with, and complimentary to, our mission.
- Lazarex has developed relationships within the FDA and NCI, and with various state and local representatives, industry stakeholders, and educational and medical institutions to work on sustainable solutions to address the inequity of access to cancer clinical trials and the barriers (esp. financial, lack of knowledge, mistrust, payer mix, etc.) that prevent access to cancer treatment.
- We have a dedicated grant writer in house.

1) We have relationships with over 200 CLINICAL TRIAL SITES nationwide.
2) By year end 2022 we assisted 1,749 patients with clinical trial participation: 964 through Lazarex CARE, 659 through Lazarex IMPACT, 4 through Lazarex PATH and 122 with clinical trial navigation. Over 11,000 patients received assistance since our inception in 2006.
3) In 2022 we reported the diversity of cancer patients we have assisted to participate in clinical trials at 33% through Lazarex CARE and 33% through the Lazarex IMPACT program. Of the Patients assisted through Lazarex CARE, 30% had household income < $25,000. Of the Patients assisted through the Lazarex IMPACT program, 40% had household income < $25,000.
4) In 2022 the Lazarex IMPACT program continued at Penn Medicine's Abramson Cancer Center (PA), UT Southwestern (TX), and 5 US Oncology locations nationwide to improve enrollment, retention and minority participation in cancer clinical trials. These IMPACT sites are funded by grant funds we've received from various pharmaceutical companies.
5) In 2020 the state of MA joined CA, PA, TX, IL and WI in passing legislation allowing that reimbursement to patients for out of pocket costs for therapeutic clinical trial participation is not considered inducement. We are working with legislators in NY, OH and FL.
6) In late 2019 we received grants from Merck ($2,000,000) and Genentech ($3,397,678) and Amgen ($500,000) to fund the launch of the IMPACT program at Penn's Abramson Cancer Center in Philadelphia and MD Anderson in Texas in 2020. This was delayed until late 2020 - 2021 due to Covid-19 slowing down the onboarding process and IRB approval.
7) We initiated the Community IMPACT pilot program in West Philadelphia with grant funds secured through the Silicon Valley Foundation. Working with Drexel University School of Public Health in Philadelphia, Lazarex Cancer Foundation is committed to building healthy communities through a novel pilot program, Community IMPACT.
8) Results from the IMPACT study in CA have been presented at various conferences in the US such as ASCO.
9) Patient brochures about Lazarex Program Services and Cancer Clinical Trial FAQs have been printed in English, Spanish, Simplified and Traditional Mandarin, Russian and Korean.
10) We have migrated away from check reimbursements to doing patient expense reimbursements with a debit card service.